FTH1P24: A Drug Target / Disease Biomarker (G100462797)
FTH1P24: A Drug Target / Disease Biomarker
FTH1P24 is a protein that is expressed in the plasma cells of individuals with multiple myeloma, a type of cancer that affects the bone marrow. The protein is made by a type of white blood cell called a plasma cell, which is a type of immune cell that produces antibodies to help fight off infections.
One of the things that makes FTH1P24 an interesting drug target is its location on the body. FTH1P24 is produced in the plasma cells, which are a part of the immune system that is responsible for producing antibodies to help fight off infections. This means that any drug that can effectively target FTH1P24 could potentially interfere with the immune system's ability to function properly.
Another reason why FTH1P24 is a potential drug target is its role in the development and progression of multiple myeloma. Multiple myeloma is a type of cancer that affects the bone marrow, and it is characterized by the production of a large number of abnormal white blood cells called leukemia cells. FTH1P24 has been shown to be involved in the production and proliferation of these leukemia cells, which may make it an attractive target for cancer researchers.
In addition to its potential role in the development and progression of multiple myeloma, FTH1P24 is also a potential biomarker for this disease. A biomarker is a substance that is produced by the body that can be used as a sign of the presence of a particular disease or condition. FTH1P24 has been shown to be elevated in the blood of individuals with multiple myeloma, which may make it an useful diagnostic tool for this disease.
FTH1P24 is also a potential drug target because it is involved in the production of antibodies, which are proteins that are produced by the immune system in response to the presence of foreign substances in the body. antibodies are able to bind to these foreign substances and help the immune system to remove them. FTH1P24 has been shown to be involved in the production of antibodies that are specific for the protein PD-L1, which is a protein that is produced by the immune system in response to the presence of a PD-1 receptor on a cancer cell.
Targeting FTH1P24 using drugs or other therapeutic agents could potentially lead to the development of new treatments for multiple myeloma and other diseases. For example, researchers may be able to use drugs that specifically bind to FTH1P24 to inhibit its production and reduce the number of leukemia cells that are produced. This could potentially lead to a more effective treatment for multiple myeloma and other diseases.
In conclusion, FTH1P24 is a protein that is expressed in the plasma cells of individuals with multiple myeloma, and it is involved in the production and proliferation of leukemia cells. As a result, it is an attractive drug target for cancer researchers, and it may also be a useful biomarker for the diagnosis and treatment of multiple myeloma. Further research is needed to fully understand the role of FTH1P24 in these processes and to develop effective treatments for this disease.
Protein Name: Ferritin Heavy Chain 1 Pseudogene 24
The "FTH1P24 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FTH1P24 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
FTH1P3 | FTH1P4 | FTH1P5 | FTH1P7 | FTH1P8 | FTHL17 | FTL | FTLP16 | FTLP2 | FTLP3 | FTLP7 | FTMT | FTO | FTO-IT1 | FTOP1 | FTSJ1 | FTSJ3 | FTX | FUBP1 | FUBP3 | FUCA1 | FUCA2 | Fucosyl GM1 | Fucosyltransferase | FUNDC1 | FUNDC2 | FUNDC2P2 | FUNDC2P3 | FUOM | FURIN | FUS | FUT1 | FUT10 | FUT11 | FUT2 | FUT3 | FUT4 | FUT5 | FUT6 | FUT7 | FUT8 | FUT8-AS1 | FUT9 | FUZ | FXN | FXR1 | FXR2 | FXYD1 | FXYD2 | FXYD3 | FXYD4 | FXYD5 | FXYD6 | FXYD6-FXYD2 | FXYD7 | FYB1 | FYB2 | FYCO1 | FYN | FYTTD1 | FZD1 | FZD10 | FZD10-AS1 | FZD2 | FZD3 | FZD4 | FZD4-DT | FZD5 | FZD6 | FZD7 | FZD8 | FZD9 | FZR1 | G protein-Coupled Inwardly-Rectifying Potassium Channel (GIRK) | G Protein-Coupled Receptor Kinases (GRKs) | G0S2 | G2E3 | G2E3-AS1 | G3BP1 | G3BP2 | G6PC1 | G6PC2 | G6PC3 | G6PD | GA-binding protein | GAA | GAB1 | GAB2 | GAB3 | GAB4 | GABA(A) receptor | GABARAP | GABARAPL1 | GABARAPL2 | GABARAPL3 | GABBR1 | GABBR2 | GABPA | GABPAP | GABPB1
